Wishing best success to all the fellows writing boards this month #MedEd #BoardPrep #HemOnc #MedTwitter #OncologyFellow #HematologyFellow
Latest posts 5
Everyone likes teaching. Nobody likes making PowerPoint slides.
We built a free tool that makes your slides from the phase 3 literature and exports to PowerPoint.
meducationai.com/tutor/signup
We built a free tool that makes your slides from the phase 3 literature and exports to PowerPoint.
meducationai.com/tutor/signup
Love seeing @RManochakian open doors for trainees like this. The pearl for fellows: regional society programs are where you meet the community oncologists who become your future referral partners, co-investigators and mentors, so go early in training, not just in your final year.
📣‼️As a proud member of @FLASCO_ORG #BoardOfDirectors, I invite #HematologyOncology colleagues, #Fellows & #Residents with #HemOnc interest to the:
⭐️ #FLASCO 2026 Fellows & Residents #TrainingProgram.
❇️ #FREE full-day program that bring together #Trainees, #ProgramDirectors and practicing #Oncologists & leaders for practical education sessions on:
✅#Board preparation
✅#Research
✅#Career development & #Mentorship
✅#Transition from training to practice
🗓️Saturday, November 21, 2026
📍JW Marriott Orlando Bonnet Creek Resort & SpaView quoted post on X
@HadidiSamer's plasma cell watch list is the one to save before New Orleans. The pearl for fellows: when two T-cell engagers are paired, read the infection and IgG replacement data as carefully as the PFS curve, because that is what decides how these regimens work in real clinics.
My top @ASH_hematology #ASH26 abstracts for plasma cell disorders including myeloma and AL amyloidosis #mmsm @utswcancer
1⃣MonumenTAL-6: Tec+Tal and Tal+Pom vs EPd/PVd ➡️Phase III, RRMM after 1–4 prior lines, all exposed to anti-CD38 and lenalidomide (80% anti-CD38-refractory)
➡️n=838; median FU: 13.4 mo
➡️Tec+Tal improved PFS HR 0.11; 12-mo PFS 89% vs 30%) and OS (HR 0.38; 12-mo OS 91% vs 80%). Tal+Pom also better than control arm (PFS HR 0.27, OS HR 0.55).
🛑Grade 3/4 infections were 312% with Tec+Tal vs 25% with control (92% of patients needed IVIG), ICANS 6%, taste changes 76% and weight loss 41% (Only 6% stopped treatment for AEs)
Time limited therapy with dual targeting in pts after anti-CD38/len failureView quoted post on X
@DrJNaidoo's framing of conversion trials is exactly right. The pearl for fellows: borderline resectable is a multidisciplinary call, not a scan finding, so the reassessment after neoadjuvant therapy is where surgery, radiation and medical oncology have to decide together.
Ph II MDT-Bridge @NatureMedicine in stage II/III NSCLC 'bridging' AEGEAN/PACIFIC:View quoted post on X
- 142pts, 92 resectable
- 50 borderline resectable→76% resectable post C2, 62% surgery, 24% CRT
Entering the era of 'conversion trials'
@Oncoalert @MartinReck2 #LCSM
nature.com/articles/s4159…
